Advances in Gamma Knife radiosurgery for pituitary tumors

2016 ◽  
Vol 23 (4) ◽  
pp. 331-338 ◽  
Author(s):  
Cheng-Chia Lee ◽  
Jason P. Sheehan
2016 ◽  
Vol 125 (Supplement_1) ◽  
pp. 160-165 ◽  
Author(s):  
Travis Hamilton ◽  
L. Dade Lunsford

OBJECTIVEThe role of Gamma Knife radiosurgery (GKRS) has expanded worldwide during the past 3 decades. The authors sought to evaluate whether experienced users vary in their estimate of its potential use.METHODSSixty-six current Gamma Knife users from 24 countries responded to an electronic survey. They estimated the potential role of GKRS for benign and malignant tumors, vascular malformations, and functional disorders. These estimates were compared with published disease epidemiological statistics and the 2014 use reports provided by the Leksell Gamma Knife Society (16,750 cases).RESULTSRespondents reported no significant variation in the estimated use in many conditions for which GKRS is performed: meningiomas, vestibular schwannomas, and arteriovenous malformations. Significant variance in the estimated use of GKRS was noted for pituitary tumors, craniopharyngiomas, and cavernous malformations. For many current indications, the authors found significant variance in GKRS users based in the Americas, Europe, and Asia. Experts estimated that GKRS was used in only 8.5% of the 196,000 eligible cases in 2014.CONCLUSIONSAlthough there was a general worldwide consensus regarding many major indications for GKRS, significant variability was noted for several more controversial roles. This expert opinion survey also suggested that GKRS is significantly underutilized for many current diagnoses, especially in the Americas. Future studies should be conducted to investigate health care barriers to GKRS for many patients.


Author(s):  
T.C. Witt ◽  
D. Kondziolka ◽  
J.C. Flickinger ◽  
L.D. Lunsford

2019 ◽  
Vol 7 (12) ◽  
pp. 1072-1075
Author(s):  
Jitendra Bhadoria ◽  
◽  
Maneet Gill ◽  
Chinmaya Srivastava ◽  
Darpan Gupta ◽  
...  

1998 ◽  
Vol 48 (Special1) ◽  
pp. 59-62
Author(s):  
Georg Norén ◽  
Ivor MD Jackson ◽  
Prakash Chougule ◽  
Zhen Zheng ◽  
Mel H Epstein

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4998
Author(s):  
Luigi Albano ◽  
Marco Losa ◽  
Lina Raffaella Barzaghi ◽  
Ajay Niranjan ◽  
Zaid Siddiqui ◽  
...  

To describe and evaluate outcomes of Gamma Knife radiosurgery (GK) for the treatment of pituitary tumors over the past twenty years, a systematic review and meta-analysis according to PRISMA statement was performed. Articles counting more than 30 patients were included. A weighted random effects models was used to calculate pooled outcome estimates. From 459 abstract reviews, 52 retrospective studies were included. Among them, 18 reported on non-functioning pituitary adenomas (NFPA), 13 on growth hormone (GH)-secreting adenomas, six on adrenocorticotropic hormone (ACTH)-secreting adenomas, four on prolactin hormone (PRL)-secreting adenomas, and 11 on craniopharyngiomas. Overall tumor control and five-year progression free survival (PFS) estimate after one GK procedure for NFPA was 93% (95% CI 89–97%) and 95% (95% CI 91–99%), respectively. In case of secreting pituitary adenomas, overall remission (cure without need for medication) estimates were 45% (95% CI 35–54%) for GH-secreting adenomas, 64% (95% CI 0.52–0.75%) for ACTH-secreting adenomas and 34% (95% CI: 19–48%) for PRL-secreting adenomas. The pooled analysis for overall tumor control and five-year PFS estimate after GK for craniopharyngioma was 74% (95% CI 67–81%) and 70% (95% CI: 64–76%), respectively. This meta-analysis confirms and quantifies safety and effectiveness of GK for pituitary tumors.


2014 ◽  
Vol 75 (S 02) ◽  
Author(s):  
V. Bulthuis ◽  
W. De Jong ◽  
Y. Yakkioui ◽  
P. Hanssens ◽  
Y. Temel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document